Coherus BioSciences said the 40 mg subcutaneous formulation of adalimumab would be launched on or after July 1, 2023, in agreement with AbbVie, maker of Humira, the reference product.
The FDA has approved a seventh adalimumab biosimilar, Yusimry (CHS-1420) developed by Coherus BioSciences. The product references Humira, a tumor necrosis factor blocker, and was approved as a 40 mg subcutaneous formulation. It is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn disease, and ulcerative colitis.
The Redwood City, California, company said that by arrangement with AbbVie, the maker of reference adalimumab (Humira), the product would not be launched until July 2023.
The 6 other makers of FDA-approved adalimumab biosimilars also have settled with AbbVie and also will delay launch until 2023. Two of these biosimilars also are launching in July 2023, another 2 adalimumab biosimilars in January and June 2023, and 2 after that, in September and November 2023.
Until now, Coherus’ sole product has been a pegfilgrastim (Udenyca), a colony stimulating factor that promotes white blood cell growth and is used in the treatment of neutropenia caused by cancer medications. Including Udenyca, there are 4 pegfilgrastim biosimilars on the US market.
“We are excited that Coherus has received FDA approval for Yusimry, our second approved product, and we are grateful to the patients and investigators who participated in our clinical trials and for the dedication of employees across all functions at Coherus,” said Denny Lanfear, CEO of Coherus.
Coherus said approval of the product was based on a randomized control study (N = 545) comparing efficacy and safety of Yusimry vs Humira in patients with moderate-to-severe chronic plaque psoriasis and also a double-blind randomized study to confirm pharmacokinetic similarity in 200 healthy subjects.
"The approval of Yusimry brings a new offering to health care practitioners and their patients with certain inflammatory diseases,” said Barbara Finck, MD, chief medical officer of Coherus.
Sales Potential
The company touted the sales potential of Yusimry, given that Humira is the world’s top selling drug and so far in the United States has no biosimilar competition. Humira had 2020 sales of roughly $20 billion globally and $16 billion in the United States.
Coherus also has an ophthalmology biosimilar under review with the FDA. This is CHS-201, which references Lucentis. The company is anticipating an FDA decision for CHS-201 in August 2022. An additional biosimilar candidate under development at Coherus is CHS-305, which references Avastin (bevacizumab).
Coherus reported 2020 sales of $476 million (mainly from Udenyca) and at the time said its pegfilgrastim biosimilar had a strong, 21% share of the overall pegfilgrastim market and a 50% share of the prefilled syringe segment. Coherus said that Udenyca together with the adalimumab and bevacizumab biosimilars would serve as the core of an immune-oncology portfolio.
The company also aims to commercialize a toripalimab product. This is a programmed death receptor-1 monoclonal antibody that prevents cancer cells from “switching off” the immune system response. This product was developed by Shanghai Junshi Bioscience of China, and Coherus is partnering with them on sales in the United States and Canada.
The FDA has granted breakthrough therapy designation to toripalimab for third-line treatment of nasopharyngeal carcinoma.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.